Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion

L. N. Maslov, Yu B. Lishmanov, J. P. Headrick, J. M. Pei, L. Hanuš, A. V. Krylatov, N. V. Naryzhnaya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.

Original languageEnglish
Pages (from-to)22-28
Number of pages7
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume75
Issue number10
Publication statusPublished - 2012

Fingerprint

Opioid Receptors
Opioid Analgesics
Reperfusion
Ischemia
Pharmaceutical Preparations
Odds Ratio
Cardiac Myocytes
Chemical activation
Apoptosis

Keywords

  • Heart
  • Ischemia
  • Opioid receptor ligands
  • Reperfusion

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion. / Maslov, L. N.; Lishmanov, Yu B.; Headrick, J. P.; Pei, J. M.; Hanuš, L.; Krylatov, A. V.; Naryzhnaya, N. V.

In: Eksperimental'naya i Klinicheskaya Farmakologiya, Vol. 75, No. 10, 2012, p. 22-28.

Research output: Contribution to journalArticle

Maslov, L. N. ; Lishmanov, Yu B. ; Headrick, J. P. ; Pei, J. M. ; Hanuš, L. ; Krylatov, A. V. ; Naryzhnaya, N. V. / Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion. In: Eksperimental'naya i Klinicheskaya Farmakologiya. 2012 ; Vol. 75, No. 10. pp. 22-28.
@article{01959fd44e464efc85bb176c35b96599,
title = "Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion",
abstract = "It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.",
keywords = "Heart, Ischemia, Opioid receptor ligands, Reperfusion",
author = "Maslov, {L. N.} and Lishmanov, {Yu B.} and Headrick, {J. P.} and Pei, {J. M.} and L. Hanuš and Krylatov, {A. V.} and Naryzhnaya, {N. V.}",
year = "2012",
language = "English",
volume = "75",
pages = "22--28",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "10",

}

TY - JOUR

T1 - Perspective of creation of drugs on basis of opioids increasing cardiac tolerance to pathogenic impact of ischemia reperfusion

AU - Maslov, L. N.

AU - Lishmanov, Yu B.

AU - Headrick, J. P.

AU - Pei, J. M.

AU - Hanuš, L.

AU - Krylatov, A. V.

AU - Naryzhnaya, N. V.

PY - 2012

Y1 - 2012

N2 - It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.

AB - It was established that δ- and K1-opioid receptor (OR) stimulation both in vivo and in vitro promotes a decrease of infarct size/area at risk (IS/AAR) ratio during ischemia and reperfusion of heart. μ-OR activation increases a tolerance of isolated perfused heart to impact of ischemia and reperfusion but has no effect on IS/AAR index in vivo. The ORL1-receptor agonist nociceptin does not exert IS/AAR ratio in vivo. δ- and κ1-OR stimulation prevents cardiomyocyte apoptosis during ischemia and reperfiision of heart. The δ- and κ1-OR agonists mimic infarct-reducing effect of postconditioning. The OR inhibition does not impact IS/AAR index both in vivo and in vitro. The δ1- , δ2- and κ1-OR agonists are the most perspective group of opioids for creation of drugs increasing cardiac tolerance to pathogenic impact of ischemia and reperfusion.

KW - Heart

KW - Ischemia

KW - Opioid receptor ligands

KW - Reperfusion

UR - http://www.scopus.com/inward/record.url?scp=84871522974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871522974&partnerID=8YFLogxK

M3 - Article

VL - 75

SP - 22

EP - 28

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 10

ER -